Theravance Biopharma(Delisted)
- Market cap
- 884.18M
- P/E (TTM)i
- 16.38
- P/Bi
- 3.05
- EPSi
- 2.06
- Div yieldi
- 0.00%
- 52W posi
- 50%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Theravance Biopharma(Delisted) closed at 17.03, little changed. At current prices, the business is worth about 884.18M, the #3330 most valuable US-listed company we track. The trailing P/E of 16.38 is 738% above its five-year average of 1.95. The shares sit 50% of the way up their 52-week range of 13.08 to 21.03.
Price chart
Key statistics
Price & volume
- Prev close
- 17.03
- Open
- 0.00
- Day range
- 0.00 - 0.00
- Avg price
- 0.00
- Volume
- 0
- Turnover
- 0
- Turnover ratei
- 0.00%
- Volume ratioi
- 0.00
- Amplitudei
- 0.00%
- 52-week rangei
- 13.08 - 21.03
Valuation
- P/Ei
- 8.27
- P/E (TTM)i
- 16.38
- P/Bi
- 3.05
- EPSi
- 2.06
- Book value / shi
- 5.58
- Net profit
- 106.95M
- Net assets
- 289.71M
Share structure
- Market cap
- 884.18M
- Float capi
- 440.57M
- Shares out
- 51.92M
- Float sharesi
- 25.87M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-10-26
19.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-11.12M net over the window
Short interest
- Shares short
- 1.69M
- % of floati
- 3.25%
- Days to coveri
- 4.50
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Theravance Biopharma(Delisted) (TBPH)?
Theravance Biopharma(Delisted) last traded at 17.03. The quote on this page refreshes every few seconds while US markets are open.
What is Theravance Biopharma(Delisted)'s market cap?
About 884.18M.
What is the P/E ratio of Theravance Biopharma(Delisted)?
The trailing twelve-month P/E is 16.38, above its own 5-year average of 1.95 — toward the top of its historical range (85.71% percentile). See the Valuation tab for the full history.
Does Theravance Biopharma(Delisted) pay a dividend?
Theravance Biopharma(Delisted) does not currently pay a regular dividend.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.